Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $1.9 million.

  • Perspective Therapeutics' Non Operating Income fell 4612.76% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 3255.72%. This contributed to the annual value of $10.5 million for FY2024, which is 115257.49% up from last year.
  • Per Perspective Therapeutics' latest filing, its Non Operating Income stood at $1.9 million for Q3 2025, which was down 4612.76% from $2.0 million recorded in Q2 2025.
  • Perspective Therapeutics' Non Operating Income's 5-year high stood at $3.7 million during Q1 2025, with a 5-year trough of $21000.0 in Q1 2021.
  • In the last 5 years, Perspective Therapeutics' Non Operating Income had a median value of $312000.0 in 2023 and averaged $1.1 million.
  • In the last 5 years, Perspective Therapeutics' Non Operating Income plummeted by 9411.76% in 2023 and then soared by 813636.36% in 2024.
  • Perspective Therapeutics' Non Operating Income (Quarter) stood at $31000.0 in 2021, then soared by 1709.68% to $561000.0 in 2022, then tumbled by 94.12% to $33000.0 in 2023, then skyrocketed by 8136.36% to $2.7 million in 2024, then plummeted by 30.39% to $1.9 million in 2025.
  • Its Non Operating Income was $1.9 million in Q3 2025, compared to $2.0 million in Q2 2025 and $3.7 million in Q1 2025.